Generated by AI
Vera Therapeutics, Inc. Class A Common Stock represents ownership in Vera Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing treatments for serious immunological diseases. The company’s current pipeline is centered on atacicept, a subcutaneous therapy being evaluated for IgA nephropathy and other autoimmune kidney diseases, alongside additional programs such as MAU868 for BK viremia infections and VT-109 for B cell-mediated autoimmune diseases. Vera Therapeutics operates in the biotechnology and health technology sectors, where its work targets conditions driven by abnormal immune activity and unmet medical needs. Headquartered in Brisbane, California, the company’s business today is centered on advancing immunology-focused drug candidates through clinical development and toward commercialization.
Website2000 Sierra Point Parkway
Brisbane, CA, 94005
United States
The latest articles about VERA.
Vera Therapeutics Inc (VERA) reported its first partial quarter of TRUTAKNA sales at $10.3 million and roughly 700 patient start forms, while advancing a supplemental BLA for full approval.
Vera Therapeutics has delivered a very strong 148.3% share price gain over the past 3 years, yet the recent pullback and mixed shorter term moves put fresh attention on what investors are actually paying for on its balance sheet. With that kind of run in the rear-view mirror and new product news in play, the open question is how today’s valuation lines up with the stock’s book value relative to the wider biotech industry. The 148.3% return over 3 years means anyone looking at Vera...
Summary of Sep 17's posts. Generated by AI.
Summary of Sep 15's posts. Generated by AI.
Summary of Jun 2's posts. Generated by AI.
Summary of Sep 17's posts. Generated by AI.
Investors talking about VERA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.